Abbott Responds On Meridia: Morbidity Standard Is Unworkable

Weight-loss drugs such as Meridia would never come to market if approvals are based on demonstrating a reduction in morbidity and mortality, Abbott maintains

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet